title: Highlights from: the American Society of Clinical Oncology Gastrointestinal Cancers Symposium, Hollywood, FL, January 2005.
authors.forename: G Kesava
authors.initials: GK
authors.lastname: Reddy
authors.forename: Tara Beers
authors.initials: TB
authors.lastname: Gibson
authors.forename: Susan
authors.initials: S
authors.lastname: Peck
authors.forename: Preeta
authors.initials: P
authors.lastname: Tyagi
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D015179:Colorectal Neoplasms / Q000000981:diagnostic imaging / Q000188:drug therapy*; D003657:Decision Making; D006801:Humans; D008113:Liver Neoplasms / Q000556:secondary; D008207:Lymphatic Metastasis; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D000077150:Oxaliplatin; D049268:Positron-Emission Tomography; D011379:Prognosis; D013534:Survival
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D000068258:Bevacizumab